In 2013, Biofarm sales rose 12% to RON117.57 million, while its profit increased by 21.7% to RON25.61 million.
The company also plans RON36 million investments this year in construction works and equipment for the new plant, but also in production, marketing and distribution.
Biofarm has a portfolio of 200 products, covering 60 therapy areas and is among the top ten medicine producers in Romania by volume.
The company’s general manager Danut Vasile said last year that Biofarm will double its production capacity and will enter new therapy areas with its relocation to a new plant in 2015, and plans to focus on developing exports.
The company is also set to reorganize and develop its export department, targeting Russia and former soviet states.
Exports currently represent 3.5% of sales, while the destinations are the Republic of Moldova, Russia, Ukraine, Azerbaijan, Belarus, Georgia, Serbia, Kazakhstan, and Hungary.
Biofarm has over 350 employees.
The company is 54.28%-owned by investment funds SIF Banat-Crisana (SIF1.RO) and SIF Muntenia (SIF4.RO). The Romanian financial supervisory authority ASF recently called on the two funds to launch a takeover bid for the remaining shares in Biofarm. (EUR1=4.5069)